医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Approval for Listing of Shares of Solasia on the Tokyo Stock Exchange Mothers

2017年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President and CEO: Yoshihiro Arai, hereinafter “Solasia”) an oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced today the approval for listing of shares on the Tokyo Stock Exchange (TSE) Mothers.

The scheduled date of the listing of the shares is Friday March 24, 2017, on or after which date the shares will be available for trading on the TSE Mothers.

The proceeds from this offering will be directed primarily to development and commercialization activities, and to execute on the company’s mission of providing “Better medicine for a brighter tomorrow”.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170220005733/en/

CONTACT

for Solasia Pharma K.K.
Rie Toyoda, +81-3-6721-8317
Investors
Relations

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 20/20’s Lung Cancer Detection Technology Launches in China
  • PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan
  • PREVENA™ Incision Management System Shown to Reduce Incisional Pain and Associated Narcotic Use Among Obese Study Patients Undergoing Cesarean Delivery
  • Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies
  • Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology